Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: Relationship to lasting effects on brain serotonin neurons

Neuropsychopharmacology

Volumn 31, Issue 2, 2006, Pages 339-350

  Mechan, Annis ^a   Yuan, Jie ^a   Hatzidimitriou, George ^a   Irvine, Rodney J ^b   McCann, Una D ^a   Ricaurte, George A ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Amphetamines; MDMA; Pharmacokinetics; Plasma; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BIOTRANSFORMATION; BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ADMINISTRATION ROUTE; FEMALE; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEROTONIN BRAIN LEVEL; SEROTONINERGIC NERVE CELL; SQUIRREL MONKEY;

3,4-METHYLENEDIOXYAMPHETAMINE; ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ELECTROCHEMISTRY; FEMALE; HALLUCINOGENS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; PROTEIN BINDING; RADIOPHARMACEUTICALS; SAIMIRI; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TIME FACTORS;

EID: 30944431901     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300808     Document Type: Article

References (69)

1. Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, Bailey JR et al (1993). Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 15: 91-96.
2. Anderson GM, Braun G, Braun U, Nichols DE, Shulgin AT (1978). Absolute configuration and psychomimetic activity. NIDA Res Monogr 22: 8-15.
3. Axt K, Mamounas L, Molliver M (1994). Structural features of amphetamine neurotoxicity. In: Cho AK, Segal DS (eds). Amphetamine and its Analogs. Academic Press: San Diego, CA. pp 315-370.
4. 3H paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242: 911-916.
5. Bendotti C, Baldessari S, Pende M, Tarizzo G, Miari A, Presti ML et al (1994). Does GFAP mRNA and mitochondrial benzodiazepine receptor binding detect serotonergic neuronal degeneration in rat? Brain Res Bull 34: 389-394.
6. Bowyer JF, Young JF, Slikker W, Itzak Y, Mayorga AJ, Newport GD et al (2003). Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24: 379-390.
7. Boxenbaum H, DiLea C (1995). First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 35: 957-966.
8. Callahan BT, Cord BJ, Ricaurte GA (2001). Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40: 113-121.
9. Chu T, Kumagai Y, DiStefano EW, Cho AK (1996). Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 51: 789-796.
10. Colado MI, Williams JL, Green AR (1995). The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115: 1281-1289.
11. Cole JC, Sumnall HR (2003). The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci Biobehav Rev 27: 199-217.
12. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN et al (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49: 104-109.
13. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M et al (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137-144.
14. Degenhardt L, Barker B, Topp L (2004). Patterns of ecstasy use in Australia: findings from a national household survey. Addiction 99: 187-195.
15. EMCDDA (2003). European Monitoring Centre for Drugs and Drug Addiction: the state of the drugs problem in the European Union and Norway: annual report. Available online at: http://annualreport.emcdda.eu.int.
16. Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G et al (2004). Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology 29: 1270-1281.
17. Farre M, de La Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M et al (2004). Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology 173: 364-375.
18. Finnegan KT, Ricaurte GA, Ritchie LD, Irwin I, Peroutka SJ, Langston JW (1988). Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res 447: 141-144.
19. Fischer CA, Hatzidimitriou G, Wlos J, Katz JL, Ricaurte GA (1995). Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). J Neurosci 15: 5476-5485.
20. Frederick DL, Paule MG (1997). Effects of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev 21: 67-78.
21. Gibb JW, Hanson GR, Johnson M (1994). Neurochemical mechanisms of toxicity. In: Cho AK, Segal DS (eds). Amphetamine and its Analogs. Academic Press: San Diego, CA. pp 269-295.
22. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508.
23. Hegadoren KM, Baker GB, Bourin M (1999). 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23: 539-553.
24. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996). Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20: 432-440.
25. Herráez-Hernández R, Campíns-Falcó P, Verdú-Andrés J (2001). Sensitive determination of methylenedioxylated amphetamines by liquid chromatography. Analyst 126: 581-586.
26. Heydari A, Rowland Yeo K, Lennard M, Ellis SW, Tucker G, Rostami-Hodjegan A (2004). The mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine (MDMA). Drug Metab Dispos 32: 1213-1217.
27. Ings RM (1990). Interspecies scaling and comparison in drug development and toxicokinetics. Xenobiotica 20: 1201-1231.
28. Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB (1989). 3,4-Methylenedioxymethamphetamine ('ecstasy') selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 249: 713-720.
29. Irvine R, Keane M, Felgate P, White J (2003). Physiological effects, blood chemistry and drug concentrations in 'club drug' users at a recreational setting. Problems of Drug Dependence: Proceedings of the 65th Annual Scientific Meeting, Bal Harbour, Florida. p 70.
30. Johnson EA, O'Callaghan JP, Miller DB (2004). Brain concentrations of d-MDMA are increased after stress. Psychopharmacology 173: 278-286.
31. Johnston LD, O'Malley PM, Bachman JG, Schulenberg E (2004). Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings 2003. NIH Publication No. 04-5506. National Institute on Drug Abuse: Bethesda, MD.
32. Jones DC, Duvauchelle C, Ikegami A, Olsen CM, Lau SS, de la Torre R et al (2005). Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J Pharmacol Exp Ther 313: 422-431.
33. Kalant H (2001). The pharmacology and toxicology of 'ecstasy' (MDMA) and related drugs. CMAJ 165: 917-928.
34. Kamien JB, Johanson CE, Schuster CR, Woolverton WL (1986). The effects of (+/-)-methylenedioxymethamphetamine and (+/-)-methylenedioxyamphetamine in monkeys trained to discriminate (+)-amphetamine from saline. Drug Alcohol Depend 18: 139-147.
35. Kleven MS, Woolverton WL, Seiden LS (1989). Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys. Brain Res 488: 121-125.
36. Kraemer T, Maurer HH (2002). Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 24: 277-289.
37. Laruelle M, Baldwin R, Malison R, Zea-Ponce Y, Zoghbi S, Al-Tikriti M et al (1993). SPECT imaging of dopamine and serotonin transporters with [123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295-309.
38. Lew R, Malberg JE, Ricaurte GA, Seiden LS (1997). Evidence for and mechanism of action of neurotoxicity of amphetamine related compounds. In: Kostrzewa RM (ed). Highly Selective Neurotoxins: Basic and Clinical Applications. Humana Press Inc.: Totowa. pp 235-268.
39. Lora-Tamayo C, Tena T, Rodriguez A, Moreno D, Sancho JR, Ensenat P et al (2004). The designer drug situation in Ibiza. Foren Sci Int 140: 195-206.
40. Mahmood I (1999). Allometric issues in drug development. J Pharmaceut Sci 88: 1101-1106.
41. Mahmood I (2002). Interspecies scaling: predicting oral clearance in humans. Am J Ther 9: 35-42.
42. Mahmood I, Green MD, Fisher JE (2003). Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43: 692-697.
43. Mordenti J, Chappell W (1989). The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V (eds). Toxicokinetics in New Drug Development. Pergamon Press: New York. pp 42-96.
44. O'Callaghan JP, Miller DB (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270: 741-751.
45. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988). Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803.
46. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN et al (2001). Effects of repeated doses of MDMA ('ecstasy') on cell-mediated immune response in humans. Life Sci 69: 2931-2941.
47. Pacifici R, Zuccaro P, Farre M, Pichini S, Di Carlo S, Roset PN et al (2002). Cell-mediated immune response in MDMA users after repeated dose administration: studies in controlled versus noncontrolled settings. Ann N Y Acad Sci 965: 421-433.
48. Parrott AC (2005). Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 19: 71-83.
49. Peters FT, Samyn N, Wahl M, Kraemer T, De Boeck G, Maurer HH (2003). Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS. J Anal Toxicol 27: 552-559.
50. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E (2003). Different glial response to methamphetamine-and methylenedioxymethamphetamine- induced neurotoxicity. Naunyn Schmiedebergs Arch Pharmacol 367: 490-499.
51. Ricaurte GA, Bryan G, Strauss L, Seiden L, Schuster C (1985). Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986-988.
52. Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1988a). Toxic effects of 3,4-methylenedioxymethamphetamine on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 446: 165-168.
53. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME et al (1988b). 3,4-Methylenedioxymethamphetamine (MDMA) selectively damages central serotonergic neurons in nonhuman primates. JAMA 260: 51-55.
54. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992). Lasting effects of (±)3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261: 616-622.
55. Rowland NE, Kalehua AN, Li BH, Semple-Rowland SL, Streit WJ (1993). Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reaction. Brain Res 624: 35-43.
56. Sadeghipour F, Veuthey JL (1997). Sensitive and selective determination of methylenedioxylated amphetamines by high-performance liquid chromatography with fluorimetric detection. J Chromatogr A 787: 137-143.
57. Samyn N, De Boeck G, Wood M, Lamers CT, De Waard D, Brookhuis KA et al (2002). Plasma, oral fluid and sweat wipe ecstasy concentrations in controlled and real life conditions. Foren Sci Int 14; 128 90-97.
58. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993). Serotonergic recovery after (+/-)3,4-(methylenedioxy)-methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264: 1484-1491.
59. Schmidt CJ (1987). Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240: 1-7.
60. Segura M, Ortuño J, Farré M, McLure JA, Pujadas M, Pizarro N et al (2001). 3,4-dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14: 1203-1208.
61. Slikker W, Ali SF, Scallet AC, Frith CH, Newport GD, Bailey JR (1988). Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 94: 448-457.
62. Slikker Jr W, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC et al (1989). Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 10: 529-542.
63. Staley J, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl J et al (2001). Gender differences in dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 41: 275-284.
64. Steele T, McCann U, Ricaurte GA (1994). 3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): pharmacology and toxicology in animals and humans. Br J Addict 89: 539-551.
65. Thomas DM, Dowgiert J, Geddes TJ, Francescutti-Verbeem D, Liu X, Kuhn DM (2004). Microglial activation is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367: 349-354.
66. Thompson DM, Winsauer PJ, Mastropaolo J (1987). Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Pharmacol Biochem Behav 26: 401-405.
67. Weir E (2000). Raves: a review of the culture, the drugs and the prevention of harm. CMAJ 162: 1843-1848.
68. Wilson MA, Mamounas LA, Fasman KH, Axt KJ, Molliver ME (1993). Reactions of 5-HT neurons to drugs of abuse: neurotoxicity and plasticity. NIDA Res Monogr 136: 155-187.
69. Wilson MA, Ricaurte GA, Molliver ME (1989). Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. J Neuroscience 28: 121-137.